TapewireFind a company

person · Reporting owner

Weiss Amir

Disclosed activity across 1 company

Tapewire entity
20121
SEC CIK
0001897057

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063Chief Accounting OfficerAugust 21, 2026August 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date August 21, 2026 · Filed August 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect13,071 Last balance in matching sequence After 2026-08-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2026-08-21 · Sale · Disposed 6,945 · Balance 13,071

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Row 2 · 2026-08-21 · Exercise / conversion · Acquired 2,500 · Balance 15,571

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Row 3 · 2026-08-21 · Sale · Disposed 2,500 · Balance 13,071

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.16 · Expires 2028-03-02Direct7,502 Reported balance After 2026-08-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-08-21 · Exercise / conversion · Disposed 2,500 · Balance 7,502

F3: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 21, 2026 Filed Aug 25, 2026 20:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionStock Options (right to buy) · Derivative 2,500 $19.16 Strike: $19.16 $47,900.00
Disclosure

SEC source: 0001193125-26-365116 · ownership.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,502

Underlying: Ordinary Shares · 2,500 shares

Expires 2028-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 2,500 $37.63 $94,076.75
Disclosure

SEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,071

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 2,500 $19.61 $49,025.00
Disclosure

SEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,571

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 21, 2026 Filed Aug 25, 2026 20:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,945 $37.61 $261,224.37
Disclosure

SEC source: 0001193125-26-365116 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,071

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 06, 2026 Filed May 7, 2026 20:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 10,679 $36.00 $384,444.00
Disclosure

SEC source: 0001193125-26-211855 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,016

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,537 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-098560 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,613

Underlying: Ordinary Shares · 3,537 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,537 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-098560 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 11,280 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 5

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,280

Underlying: Ordinary Shares · 11,280 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,650 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,300

Underlying: Ordinary Shares · 5,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 10,679 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096459 · ownership.xml · derivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 10,679 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,650 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096459 · ownership.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,158

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 10,679 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096459 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,179 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093963 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,180

Underlying: Ordinary Shares · 5,179 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,179 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093963 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
December 16, 2025 Filed Dec 18, 2025 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 12,300 $30.20 $371,504.28
Disclosure

SEC source: 0001193125-25-324789 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,650

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $30.205, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
November 06, 2025 Filed Nov 10, 2025 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 12,300 $24.44 $300,564.03
Disclosure

SEC source: 0001193125-25-274204 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,950

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.435 to $24.455, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:29 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 14,150 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035542 · ownership.xml · derivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Ordinary Shares · 14,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 3,537 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 3,537 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:29 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,566 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035542 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,566 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 3,566 vested on March 5, 2025.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 3,566 vested on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:29 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,566 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-035542 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,650 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034707 · ownership.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,950

Underlying: Ordinary Shares · 5,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on March 4, 2025, and 5,650 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vested on March 4, 2025, and 5,650 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 10,676 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034707 · ownership.xml · derivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,679

Underlying: Ordinary Shares · 10,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,650 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034707 · ownership.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 10,676 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034707 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,179 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-033628 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,359

Underlying: Ordinary Shares · 5,179 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024 and March 3, 2025, 5,179 vesting on March 3, 2026, and 5,180 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vested on each of March 3, 2024 and March 3, 2025, 5,179 vesting on March 3, 2026, and 5,180 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,179 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-033628 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
May 16, 2024 Filed May 17, 2024 11:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 12,635 $16.65 $210,376.54
Disclosure

SEC source: 0000950170-24-061334 · ownership.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,179

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.655, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 15, 2024 Filed May 17, 2024 11:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 15,500 $16.80 $260,417.05
Disclosure

SEC source: 0000950170-24-061334 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,814

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.800 to $16.805, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,564 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-027944 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,566

Underlying: Ordinary Shares · 3,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,564 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-027944 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 22,600 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 5

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,600

Underlying: Ordinary Shares · 22,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 5,650 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 5,650 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 10,676 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,355

Underlying: Ordinary Shares · 10,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023 and March 4, 2024, 10, 676 vesting on March 4, 2025 and 10,679 vesting on March 4, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023 and March 4, 2024, 10, 676 vesting on March 4, 2025 and 10,679 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 10,676 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025863 · ownership.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,179 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025863 · ownership.xml · derivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,538

Underlying: Ordinary Shares · 5,179 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,179 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025863 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:48 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,219 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023526 · ownership.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023, and February 28, 2024.

F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023, and February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:48 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,219 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-023526 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,895

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 12:49 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 31,766 $12.37 $392,954.95
Disclosure

SEC source: 0000950170-24-011009 · ownership.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,676

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.37 to $12.375, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
August 04, 2023 Filed Aug 7, 2023 20:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 1,981.41 $9.92 $19,657.57
Disclosure

SEC source: 0001209191-23-044806 · doc4.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,442

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.91 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 7

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,130

Underlying: Ordinary Shares · 3,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025.

F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 3

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,204.41

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 10,676 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 6

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,031

Underlying: Ordinary Shares · 10,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023, 10,676 vesting on each of March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2026.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vested on March 4, 2023, 10,676 vesting on each of March 4, 2024 and March 4, 2025, and 10,679 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 2,406 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 5

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,406 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 2,403 vested on each of March 4, 2021 and March 4, 2022, and 2,406 vested on March 4, 2023.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 2,403 vested on each of March 4, 2021 and March 4, 2022, and 2,406 vested on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 10,676 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,640.41

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 2,406 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,964.41

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:15 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 20,717 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016723 · doc4.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,717

Underlying: Ordinary Shares · 20,717 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:39 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,219 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-014443 · doc4.xml · derivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,219

Underlying: Ordinary Shares · 3,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 3,219 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 3,219 vesting on February 28, 2024.

F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 3,219 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 3,219 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:39 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,219 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-014443 · doc4.xml · nonDerivative · entry 1

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,777.41

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:14 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017066 · doc4.xml · derivative · entry 5

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,694

Underlying: Ordinary Shares · 3,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 3,564 having vested on March 5, 2022, 3,564 vesting on each of March 5, 2023 and March 5, 2024 and 3,566 vesting on March 5, 2025.

F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 3,564 having vested on March 5, 2022, 3,564 vesting on each of March 5, 2023 and March 5, 2024 and 3,566 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:14 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017066 · doc4.xml · nonDerivative · entry 2

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,558.41

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:14 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 42,707 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017066 · doc4.xml · derivative · entry 4

Weiss Amir · CIK 0001897057 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,707

Underlying: Ordinary Shares · 42,707 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 10,676 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025 and 10,679 vesting on March 4, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 10,676 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025 and 10,679 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.